MLYS: AZN's Baxfendy Label Broadly In Line with Our (and MLYS Mgmt’s) Expectations with No Obvious Advantages Over Lorundrostat, Leaving Room for BIC Label; Baxfendy Price ($900/Mo) Should Allow BOTH Products to Achieve Multi-blockbuster Status

Research evidence excerpt

MLYS: AZN's Baxfendy Label Broadly In Line with Our (and MLYS Mgmt’s) Expectations with No Obvious Advantages Over Lorundrostat, Leaving Room for BIC Label; Baxfendy Price ($900/Mo) Should Allow BOTH Products to Achieve Multi-blockbuster Status

ment adviser, “GSRS,”

and together with Guggenheim Securities, “Guggenheim”). If you are paying separately for this research, it is being provided to you by GSRS. Otherwise, it

is being provided by Guggenheim Securities. Guggenheim does not create tailored or personalized research and all research provided by Guggenheim is

impersonal advice. Other than disclosures relating to Guggenheim and our affiliates, this research is based on current public information that we consider

reliable, but we do not represent it is accurate or complete, and it should not be relied on as such. Portions of the research contained herein have been

generated using artificial intelligence ("AI"). We primarily use AI to gather general market or industry data and to compile company-specific information

to facilitate the recipient's preliminary review. In providing this research, we assume that any information obtained from public sources, data suppliers

(including AI systems) and other third parties is reasonable and reliable but acknowledge that any such information (including AI content) could contain

errors, inconsistencies, bias or outdated or irrelevant information. We seek to update our research as appropriate, but various regulations may prevent

us from doing so. Other than certain industry reports published on a periodic basis, the large majority of reports are published at irregular intervals as

appropriate in the research analyst's judgement. Guggenheim Securities conducts a full-service, integrated investment banking and brokerage business.